A Phase 2/3 interventional study of adalimumab and adalimumab in Crohn's Disease, sponsored by Abbott. Completed at 18 sites in Japan. Open to participants aged 15 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-06-27.
Sponsored by Abbott · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.
Among the 42 studies testing adalimumab in Crohn Disease, this one is the 28th largest by enrollment, is one of 4 that started in 2007, is one of 2 in phase 2/3, and was the 11th registered.
1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 6–17
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18–70
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 15 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 24 · Phase 4 13
First in 2002; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 143 across the 42 interventional studies. Of the 32 that completed or were terminated, 19 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 42 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
17 studies in Crohn Disease by Abbott: none open now, none under way, none of them phase 3. Of 17 finished, 9 (53%) have results posted.
Among the 17 studies in Crohn Disease by Abbott, this one is the 14th largest by enrollment, is one of 5 that started in 2007, is one of 2 in phase 2/3, and was the 14th registered.
Abbott’s Crohn Disease studies by the year they started, since 2002.
1 of the studies testing adalimumab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing adalimumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 17 in Crohn Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: adalimumab
Biological: adalimumab
Biological: placebo
160 mg at Week 0, 80 mg at Week 2
Also known as: ABT-D2E7, Humira
80 mg at Week 0, 40 mg at Week 2
Also known as: ABT-D2E7, Humira
Placebo at Week 0 and Week 2
The Number of Subjects With a Clinical Remission (Crohn's Disease Activity Index [CDAI] < 150) at Week 4
CDAI is used to quantify the symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Comparison of the number of subjects with a clinical remission (CDAI \< 150) in the adalimumab 160 mg (Week 0)/ 80 mg (Week 2) and adalimumab 80 mg (Week 0)/ 40 mg (Week 2) groups at Week 4.
Time frame: 4 Weeks
Clinical Remission (CDAI < 150) at Week 2
Number of subjects in each treatment group in clinical remission (CDAI \< 150) in Full Analysis Set (FAS) using non-responder Imputation (NRI) at Week 2.
Time frame: Week 2
Clinical Response (CR-70 and CR-100) in Period A
The number of subjects in each treatment group with a clinical response 70 (CDAI decrease of \>=70 compared to Baseline) and 100 (CDAI decrease of \>=100 compared to Baseline) at Week 2 and Week 4.
Time frame: Weeks 2 and Week 4
Clinical Response (CR-70 and CR-100) in Period B
The Number of subjects in each treatment group with a CR-70 (CDAI decrease of \>= 70 compared to Baseline) and 100 (CDAI decrease of \>= 100 compared to Baseline) in subjects who were non-responders at Week 4 at Week 6 and Week 8.
Time frame: Week 6 and Week 8
Clinical Remission (CDAI <150) at Week 6 and Week 8
The number of subjects with clinical remission (CDAI \< 150) in the subjects who were non-responders at Week 4 calculated with non-responder imputation (NRI) at Week 6 and Week 8
Time frame: Week 6 and Week 8
Subjects with moderate to severe Crohn's Disease (Crohn's Disease Activity Index \[CDAI\] \>= 220 and \<= 450) were enrolled into study. The period from the first dose of study drug to the evaluation at Week 4 is Period A. The period from the study drug injection at Week 4 to the evaluation at Week 8 is Period B.
| Milestone | Adalimumab 160 mg/80 mg | Adalimumab 80 mg/40 mg | Placebo | Adalimumab 40mg /40 mg |
|---|---|---|---|---|
| Started | 33 | 34 | 23 | 0 |
| Completed | 32 | 32 | 23 | 0 |
| Not completed | 1 | 2 | 0 | 0 |
| Withdrew: Adverse event | 1 | 2 | 0 | 0 |
| Milestone | Adalimumab 160 mg/80 mg | Adalimumab 80 mg/40 mg | Placebo | Adalimumab 40mg /40 mg |
|---|---|---|---|---|
| Started | 16 | 0 | 0 | 21 |
| Completed | 14 | 0 | 0 | 20 |
| Not completed | 2 | 0 | 0 | 1 |
| Withdrew: Adverse event | 2 | 0 | 0 | 1 |
CDAI is used to quantify the symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Comparison of the number of subjects with a clinical remission (CDAI \< 150) in the adalimumab 160 mg (Week 0)/ 80 mg (Week 2) and adalimumab 80 mg (Week 0)/ 40 mg (Week 2) groups at Week 4.
| Particpants | Adalimumab 160 mg/80 mg | Adalimumab 80 mg/40 mg | Placebo |
|---|---|---|---|
| The Number of Subjects With a Clinical Remission (Crohn's Disease Activity Index [CDAI] < 150) at Week 4 | 11 | 6 | 3 |
Number of subjects in each treatment group in clinical remission (CDAI \< 150) in Full Analysis Set (FAS) using non-responder Imputation (NRI) at Week 2.
| Participants | Adaliumab 160 mg/80 mg | Adalimumab 80 mg/40 mg | Placebo + 160/80 mg |
|---|---|---|---|
| Week 2 | 6 | 5 | 1 |
The number of subjects in each treatment group with a clinical response 70 (CDAI decrease of \>=70 compared to Baseline) and 100 (CDAI decrease of \>=100 compared to Baseline) at Week 2 and Week 4.
| participants | Adaliumab 160 mg/80 mg | Adalimumab 80 mg/40 mg | Placebo |
|---|---|---|---|
| CR-70 at Week 2 | 15 | 17 | 4 |
| CR-70 at Week 4 | 23 | 20 | 7 |
| CR-100 at Week 2 | 10 | 11 | 2 |
| CR-100 at Week 4 | 15 | 17 | 4 |
The Number of subjects in each treatment group with a CR-70 (CDAI decrease of \>= 70 compared to Baseline) and 100 (CDAI decrease of \>= 100 compared to Baseline) in subjects who were non-responders at Week 4 at Week 6 and Week 8.
| Participants | Adaliumab 160 mg/80 mg + 40/40 mg | Adalimumab 80 mg/40 mg + 40/40 mg | Placebo + Adalimumab 160/80 mg |
|---|---|---|---|
| CR-70 at Week 6 | 1 | 4 | 9 |
| CR-70 at Week 8 | 3 | 5 | 12 |
| CR-100 at Week 6 | 0 | 1 | 3 |
| CR-100 at Week 8 | 0 | 2 | 7 |
The number of subjects with clinical remission (CDAI \< 150) in the subjects who were non-responders at Week 4 calculated with non-responder imputation (NRI) at Week 6 and Week 8
| Participants | Adaliumab 160 mg/80 mg + 40/40 mg | Adalimumab 80 mg/40 mg + 40/40 mg | Placebo + Adalimumab 160/80 mg |
|---|---|---|---|
| Clinical Remission at Week 6 | 0 | 1 | 2 |
| Clinical Remission at Week 8 | 0 | 1 | 2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adaliumab 160 mg/80 mg | — | — | — |
| Adalimumab 80 mg/40 mg | — | — | — |
| Placebo | — | — | — |
| Adalimumab 160 mg/80 mg + 40/40 mg | — | — | — |
| 80/40 mg + 40/40 mg | — | — | — |
| Placebo + Adalimumab 160/80 mg | — | — | — |
| Event | Adaliumab 160 mg/80 mg | Adalimumab 80 mg/40 mg | Placebo | Adalimumab 160 mg/80 mg + 40/40 mg | 80/40 mg + 40/40 mg | Placebo + Adalimumab 160/80 mg |
|---|---|---|---|---|---|---|
| Crohn's DiseaseGastrointestinal disorders | 0/33 | 2/34 | 2/23 | 1/9 | 1/12 | 0/16 |
| EpididymitisReproductive system and breast disorders | 1/33 | 0/34 | 0/23 | 0/9 | 0/12 | 0/16 |
| Abdominal abcessInfections and infestations | 0/33 | 1/34 | 0/23 | 0/9 | 0/12 | 0/16 |
| C-reactive protein increased (at investigator's discretion)Investigations | 0/33 | 1/34 | 0/23 | 0/9 | 0/12 | 0/16 |
| SubileusGastrointestinal disorders | 0/33 | 1/34 | 0/23 | 0/9 | 0/12 | 0/16 |
| Event | Adaliumab 160 mg/80 mg | Adalimumab 80 mg/40 mg | Placebo | Adalimumab 160 mg/80 mg + 40/40 mg | 80/40 mg + 40/40 mg | Placebo + Adalimumab 160/80 mg |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/33 | 1/34 | 0/23 | 1/9 | 1/12 | 3/16 |
| HeadacheNervous system disorders | 3/33 | 0/34 | 1/23 | 0/9 | 2/12 | 1/16 |
| NauseaGastrointestinal disorders | 1/33 | 1/34 | 3/23 | 0/9 | 0/12 | 0/16 |
| Adverse drug reactionGeneral disorders | 1/33 | 1/34 | 1/23 | 1/9 | 0/12 | 0/16 |
| Application site swellingGeneral disorders | 0/33 | 0/34 | 0/23 | 1/9 | 0/12 | 0/16 |
| Blood creatine phosphokinase (at investigator's discretion)Investigations | 0/33 | 1/34 | 0/23 | 1/9 | 0/12 | 0/16 |
| Chest painGeneral disorders | 0/33 | 0/34 | 0/23 | 1/9 | 0/12 | 0/16 |
| Feeling abnormalGeneral disorders | 0/33 | 0/34 | 0/23 | 1/9 | 0/12 | 0/16 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/33 | 0/34 | 0/23 | 1/9 | 0/12 | 0/16 |
| Instillation site painGeneral disorders | 0/33 | 0/34 | 0/23 | 1/9 | 0/12 | 0/16 |
| Age Continuous(years) | Adalimumab 160 mg/80 mg | Adalimumab 80 mg/40 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 32.0 ± 9.60 | 30.6 ± 9.26 | 30.4 ± 6.93 | 31.1 ± 8.80 |
| Sex: Female, Male(Participants) | Adalimumab 160 mg/80 mg | Adalimumab 80 mg/40 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 13 | 18 | 7 | 38 |
| Male | 20 | 16 | 16 | 52 |
| Region of Enrollment(participants) | Adalimumab 160 mg/80 mg | Adalimumab 80 mg/40 mg | Placebo | Total |
|---|---|---|---|---|
| Japan | 33 | 34 | 23 | 90 |
The record gives a start of Feb 2007 and a primary completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab